Lukasz Kuryk | Immunology and Microbiology | Research Excellence Award

Lukasz Kuryk | Immunology and Microbiology | Research Excellence Award

National Institute of Public Health | Poland

Łukasz Kuryk, PhD, is a preclinical immuno-oncology researcher whose work centers on advancing next-generation oncolytic adenoviruses and innovative immune-based cancer therapies through rigorous translational development. With extensive expertise spanning preclinical drug development—including efficacy, safety, biodistribution, and mechanistic immunology—he has contributed significantly to the evolution of modern virotherapy and cancer immunotherapy platforms. As a Principal Investigator leading national and international research initiatives, he develops and evaluates novel viral and immune-modulating therapeutics with the goal of enhancing antitumor immunity and improving clinical outcomes. His career includes impactful roles at the National Institute of Public Health in Poland, where he has served as Associate Professor and Assistant Professor in the Department of Virology, driving research in immuno-oncology and cancer vaccine development. He has also contributed to pioneering studies at the Warsaw University of Technology within the Immuno-Oncology and Immunotherapy Laboratory, working at the interface of engineering, immunology, and infectious disease research. His international engagement includes work as a visiting researcher at the University of Padova, where he explored the use of EV-like nanoparticles as delivery platforms for oncolytic viruses, opening new avenues for therapeutic innovation. A co-inventor on multiple patents in oncolytic virotherapy and cancer vaccine technologies, he is recognized for fostering highly productive academic–industry collaborations that accelerate the translation of experimental therapeutics toward clinical relevance. He has authored more than fifty peer-reviewed publications that contribute to the expanding understanding of viral immunotherapies and tumor–immune interactions, establishing him as an influential scientist in the field. His career reflects a persistent commitment to advancing the scientific foundations and therapeutic potential of immuno-oncology through multidisciplinary collaboration, innovation, and translational impact.

Featured Publications

Mathlouthi, S., Kuryk, L., Rinner, B., Bellio, G., Casagrande, L., Pesce, C., Fragassi, A., Salmaso, S., Mastrotto, F., & Garofalo, M. (2026). A 3D coculture model of hepatocellular carcinoma: Addressing challenges with glycopolymers re-targeted oncolytic viruses. Journal of Drug Delivery Science and Technology, 107658.

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Data 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Figures S1 to S7 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Methods 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Table 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma

Jacob Gopas | Immunology and Microbiology | Best Researcher Award

Jacob Gopas | Immunology and Microbiology | Best Researcher Award

Prof Jacob Gopas, Ben-Gurion University of the Negev, Israel

Professor Jacob Gopas is a distinguished Israeli-Mexican biomedical scientist renowned for his contributions to cancer immunology and biomedical ethics. Born on February 4, 1954, in Mexico City, he pursued an academic career that spans microbiology, immunology, and cancer research. He earned his Ph.D. from the Albert Einstein College of Medicine in New York and has held various prestigious academic positions at Ben-Gurion University of the Negev. He served as Head of the Oncology Laboratory at Soroka Medical Center for over 35 years. In addition to his research, Professor Gopas has played pivotal roles in national and institutional ethics committees, significantly shaping animal experimentation policy in Israel. As a professor in the Faculty of Health Sciences, he has trained generations of students in microbiology and cancer biology. His interdisciplinary research has addressed Hodgkin’s lymphoma, novel anti-cancer compounds, and the impact of sleep apnea on cardiac cells, supported by prestigious international and national grants.

Publication Profile

google scholar

Education

Jacob Gopas began his academic journey with a B.Sc. in Microbiology (1971–1975) at Bar-Ilan University, Ramat Gan, Israel. He continued at Bar-Ilan for his M.Sc. (1975–1977) under Prof. Arye Rozenszajn, researching the impact of hemopoietic factors on lymphocyte colony formation. He then earned a Ph.D. in Cell Biology (1977–1982) from the Albert Einstein College of Medicine, New York, under Dr. Stanley Nathanson, focusing on MHC gene variants and immune responses. Following this, he completed a post-doctoral fellowship (1982–1983) at Ben-Gurion University under Prof. Shraga Segal in microbiology and immunology. Later, from 1994 to 1997, he expanded into health policy and leadership by completing a Master’s in Health Management at Ben-Gurion University. His academic training encompasses a rich mix of molecular biology, immunogenetics, and clinical science, positioning him as a leader in translational cancer research and ethical practice in biomedical sciences.

Experience

Prof. Jacob Gopas has over four decades of academic and research experience. He began as a teaching assistant at Bar-Ilan and Yeshiva Universities and joined Ben-Gurion University in 1983 as a lecturer. He rose through the ranks, becoming a senior lecturer (1993), associate professor (2000), and full professor in 2014. From 1986 to 2022, he led the Oncology Laboratory at Soroka Medical Center, advancing cancer research and diagnostics. He held visiting scientist positions at the NIH and SUNY Health Science Center and was a fellow of the EORTC, EACR, and UICC. Prof. Gopas also led key university roles, such as Head of Recanati School for Community Health Professions, Head of Ethics Committees, and member of national ethics boards including the Israel Ministry of Health’s IACUC. His leadership has influenced both scientific innovation and ethical governance in Israeli biomedical research.

Awards and Honors

Prof. Jacob Gopas has been honored with multiple prestigious fellowships and appointments throughout his career. His notable awards include fellowships from the European Organization for Research and Treatment of Cancer (EORTC), the European Association for Cancer Research (EACR), and the International Union Against Cancer (UICC). These fellowships recognize his groundbreaking work in cancer biology and immunogenetics. His leadership in research ethics is equally commendable—he served as Head of the National Agency of Ethics in Animal Experimentation under the Israel Ministry of Health from 2016 to 2022, influencing policy at a national level. He was a member of the executive committee of the Israel Association for Cancer Research (IACR) (2021–2024) and represented the Israel National Academy of Sciences in ethical regulation. His achievements reflect a blend of scientific rigor, institutional leadership, and deep commitment to the responsible advancement of biomedical science.

Research Focus

Prof. Jacob Gopas’s research spans cancer biology, immunology, and translational medicine. His primary focus is the pathogenesis of Hodgkin’s lymphoma, particularly the molecular and immunological mechanisms behind its development and progression. He also investigates the development of natural compounds with anti-cancer, antimicrobial, and anti-inflammatory properties, aiming to identify effective, low-toxicity therapies. Another of his innovative projects explores the impact of obstructive sleep apnea on stem cell-derived human cardiomyocytes, linking sleep disorders with cardiovascular pathology. His interdisciplinary research integrates cell biology, molecular genetics, immunology, and pharmacology. Funded by agencies such as the NIH, Israel Ministry of Health, Israel Cancer Association, and Israel Science Foundation, his work has contributed to new therapeutic insights and ethical frameworks. Through collaborations, including with the Fox Chase Cancer Center, he continues to push boundaries in both laboratory science and clinical application, while mentoring emerging scientists in translational biomedical research.

Publication Top Notes

  1. Induction of B-lymphocyte colony growth in vitro by thymus derived stimulating factor.

  2. Lymphocyte colony growth in vitro.

  3. Mutants of the murine major histocompatibility complex: structural analysis of in vivo and in vitro H-2K variants.

  4. Analysis of somatic cell H-2 variants to define the structural requirements for class I expression.

  5. The immunobiology of metastatic processes: analysis of NK sensitivity and the metastatic potential of H-2 gene transfected fibrosarcoma cells.

  6. NK sensitivity, H-2, Ki-ras protooncogene expression and metastasis: Analysis of the metastatic potential of H-2 gene transfected fibrosarcoma cells.

  7. Influence of H-2K transfection on susceptibility of fibrosarcoma tumor cells to natural killer (NK) cells.

  8. The relationship between MHC antigen expression and metastasis.

  9. Nephrotic syndrome associated with cell carcinoma of the bladder.

  10. The influence of murine and human major histocompatibility complex class I expression on tumor growth and metastasis.

Pankaj Kumar | Immunology and Microbiology | Best Researcher Award

Pankaj Kumar | Immunology and Microbiology | Best 

Pankaj Kumar,The Ohio State University,United States

Pankaj Kumar is a Ph.D. researcher at Ohio State University. His research focuses on cancer biology, immunotherapy, and molecular mechanisms. He has published several papers and received awards for his work.

Publication Profile

orcid

Education

Pankaj Kumar completed his Ph.D. in Molecular and Cancer Biology from CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) Hyderabad, India (2014-2021). He received his M.S. in Biotechnology from Babasaheb Bhimrao Ambedkar University (BBAU), Lucknow, India (2011-2013) and B.S. in Biotechnology from Chhatrapati Shahu Ji Maharaj University (CSJMU), Kanpur, India (2008-2011).

Experience

Pankaj Kumar worked as a Postdoctoral Research Scholar at Ohio State University (February 2021-present). He was a Research Fellow (Ph.D.) at CSIR-Centre for Cellular and Molecular Biology, Hyderabad (August 2014-October 2021).

Awards And Honors

Pankaj Kumar received the Keystone Symposia travel award (2019), Carl Storm International Diversity (CSID) fellowship (2018), International Travel grant from ICMR-India (2018), CSIR-NET (Junior/Senior Research Fellowship-2015), and DBT-JRF (Junior Research Fellowship-2014).

Research Focus

Pankaj Kumar’s research focuses on cancer biology, immunotherapy, molecular mechanisms, and drug resistance. His work explores the molecular basis of cancer, multidrug resistance, tumor metastasis, and cancer immunotherapy.

Publications

  1. Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation however independent of tumor progression 📄
  2. The matrix metalloproteinase 7 (MMP7) links Hsp90 chaperone with acquired drug resistance and tumor metastasis 📄
  3. Altered molecular pathways decides the treatment outcome of Hsp90 inhibitors against breast cancer cells 📄
  4. Targeting squalene epoxidase interrupts homologous recombination via the ER stress response and promotes radiotherapy efficacy 📄
  5. Heat shock transcription factor HSF2 modulates the autophagy response through the BTG2-SOD2 axis 📄
  6. Effect Of OSU-ERβ-12, A Carborane-based ERβ-selective Agonist, On Hepatic Fibrosis And NASH 📄
  7. The Battle of LPS Clearance in Host Defense vs. Inflammatory Signaling 📄